Zucara Therapeutics Inc.

Zucara Therapeutics Inc.

is a biopharmaceutical company focused on developing ZT-01, a once-daily therapeutic aimed at preventing hypoglycemia in patients with diabetes, particularly those with Type 1 diabetes and insulin-dependent Type 2 diabetes. Founded in December 2014, Zucara operates from offices in Toronto, Ontario, and Vancouver, British Columbia. The company is currently in Phase 2 Clinical Studies for ZT-01, having secured funding following positive proof-of-concept data in 2022 and completing a US$25 million Series B financing in 2025. ZT-01 is a novel peptide therapy delivered via subcutaneous injection. It works by blocking somatostatin type 2 receptors in the pancreas, which helps restore glucagon secretion, the body's natural defense against low blood sugar. This preventative approach is designed for patients with a history of severe, recurrent hypoglycemia, addressing a significant need among the approximately 2 million patients worldwide with Type 1 diabetes at risk of such episodes. Zucara is also exploring additional peptide therapies for non-muscle invasive bladder cancer, expanding its focus beyond diabetes.